Consonance Capital Management is a fund manager in New York with $44.43 mm assets under management.
Company profile
Website
Employees
Incorporated
Location
Fiscal year end
Industry
SEC CIK
IRS number
260294313
SEC advisor number
801-75000
FINRA CRD number
162717
AUM ?
$44.43 mm
(as of 22 Dec 22)
Accounts
6
(as of 22 Dec 22)
Employees
4
(3 investment advisory or research)
Address
Consonance Capital Management
1370 AVENUE OF THE AMERICAS
SUITE 3301
NEW YORK
NY 10019
1370 AVENUE OF THE AMERICAS
SUITE 3301
NEW YORK
NY 10019
Office hours
Monday - Friday, 9:00AM - 6:00PM
Phone
212.660-8062
Ownership
Owner | Title | From | %Ownership |
---|---|---|---|
Blutt, Mitchell, Jonathan | Founder, Partner & Chief Executive Officer | 07/2007 | < 5% |
Livingston, Kevin, Harold | Founder & Partner | 07/2007 | 10-25% |
Consonance Capman GP LLC | General Partner | 07/2007 | 25-50% |
Soffer, Benny, NMN | Founder & Partner | 07/2007 | 25-50% |
Blutt, Mitchell, Jonathan | Manager and Member | 12/2007 | > 75% |
Franco, Gabriela, Judith | Chief Financial Officer and Chief Compliance Officer | 12/2021 | < 5% |
Ownership
Fund structure | AUM | Fund type |
---|---|---|
Consonance Capital Management LP | $44.43 mm | |
Consonance Capital Master Account LP | $27.48 mm | Hedge Fund |
Consonance Capital Investors LP | ||
Consonance Capital Investors LTD | ||
Consonance Capital Opportunity Master Fund, LP | $16.94 mm | Hedge Fund |
Consonance Capital Opportunity Fund, LP | ||
Consonance Capital Opportunity Fund, LTD. |
Latest filings (excl ownership)
No filings
Latest ownership filings
SC 13D/A
Surrozen, Inc./DE
15 Dec 22
4
MITCHELL J MD BLUTT
15 Dec 22
13F-HR
Quarterly holdings report by institutional manager
14 Nov 22
13F-HR
Quarterly holdings report by institutional manager
15 Aug 22
13F-HR
Quarterly holdings report by institutional manager
16 May 22
SC 13G/A
Cellectar Biosciences, Inc.
14 Feb 22
SC 13G/A
Sio Gene Therapies Inc.
14 Feb 22
SC 13G/A
Protagonist Therapeutics, Inc
14 Feb 22
SC 13G/A
GenMark Diagnostics, Inc.
14 Feb 22
SC 13G/A
Gamida Cell Ltd.
14 Feb 22